Advertisement

Pharmacokinetics of Exogenous Natural and Synthetic Estrogens and Antiestrogens

  • W. Kuhnz
  • H. Blode
  • H. Zimmermann
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 135 / 2)

Keywords

High Performance Liquid Chromatographic Grapefruit Juice Amino Glutethimide Conjugate Equine Estrogen Synthetic Estrogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abdel-Aziz MT, Williams KIH(1970)Metabolism of radioactive 17 a-ethynylestradiol by women. Steroids 15:695–710PubMedCrossRefGoogle Scholar
  2. Abernethy DR, Greenblatt DJ, Divoli M, Arendt R, Ochs HR, Shader RI(1982)Impairment of diazepam metabolism by low-dose estrogen-containing oral contraceptive steroids. New England J Med 306:791–792CrossRefGoogle Scholar
  3. Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hamalainen E(1994) Estrogen metabolism and excretion in oriental and caucasian women. J Natl Cancer Inst 86:1076–1082PubMedCrossRefGoogle Scholar
  4. Adlercreutz H, Martin F(1980)Biliary excretion and intestinal metabolism of progesterone and estrogens in man. J Steroid Biochem 13:231–244PubMedCrossRefGoogle Scholar
  5. Adlercreutz H, Martin F, Jarvenpaa P, Fotsis T(1979)Steroid absorption and enterohepatic recycling. Contraception 20:201–223PubMedCrossRefGoogle Scholar
  6. Aedo AR, Sunden M, Landgren BM, Diczfalusy E(1989)Effect of orally administered estrogens on circulating profiles in postmenopausal women. Maturitas 11:159–168PubMedCrossRefGoogle Scholar
  7. Agnihotri A, Srivastava AK, Kamboj VP(1996)Characterization of centchroman binding protein in plasma of rhesus monkey (macaca mulatta), J Med Primatol 25:53–56PubMedCrossRefGoogle Scholar
  8. Akpoviroro JO, Fotherby K(1980)Assay of ethynyloestradiol in human serum and its binding to plasma proteins. J Steroid Biochem 13:773–779PubMedCrossRefGoogle Scholar
  9. Akpoviroro JO, Mangalam M, Jenkins N, Fotherby K(1981)Binding of the contraceptive steroids medroxyprogesterone acetate and ethynyloestradiol in blood of various species. J Steroid Biochem 14:493–498PubMedCrossRefGoogle Scholar
  10. Anderson F(1993)Kinetics and pharmacology of estrogens in pre- and postmenopausal women. Int J Fertil 38 (Suppl) 1:53–64Google Scholar
  11. Ansbacher R(1993)Bioequivalence of Conjugated Estrogen Products. Clin Pharmacokinet 24:271–274PubMedCrossRefGoogle Scholar
  12. Anttila M, Valavaara R, Kivinen S, Maenpaa J(1990)Pharmacokinetics of toremifene. 1. Steroid Biochem. 36:249–252CrossRefGoogle Scholar
  13. Anttila M, Laakso S, Nylanden P, Sotaniemi EA(1995)Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin Pharmacol Ther 57:628–635PubMedCrossRefGoogle Scholar
  14. Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orme MLE, Rowe PH, Watts MJ(1979)An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. Contraception 20:263–273PubMedCrossRefGoogle Scholar
  15. Back DJ, Bates M, Breckenridge AM, Crawford FE, Ellis A, Hall JM, McIver M, Orme MLE, Rowe PH (1980a)Drug metabolism by gastrointestinal mucosa: Clinical aspects. In: Prescot, Nimmo, (eds) Drug absorption. Sydney, Adis Press, pp 80–87Google Scholar
  16. Back DJ, Bates M, Bowden A, Breckenridge AM, Hall MJ, Jones H, MacIver M, Orme MLE, Perucca A, Richens A, Rowe PH, Smith E(1980b)The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 22:495–503PubMedCrossRefGoogle Scholar
  17. Back DJ, Breckenridge AM, Crawford FE, Hall JM, MacIver M, Orme MLE, Rowe PH, Smith E, Watts MJ(1980c)The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception 21:135–143PubMedCrossRefGoogle Scholar
  18. Back DJ, Breckenridge AM, Crawford FE, Orme MLE, Rowe PH(1980d)Phenobarbitone interaction with oral contraceptive steroids in the rabbit and rat. Br J Pharmacol 69:441–452PubMedGoogle Scholar
  19. Back DJ, Bolt HM, Breckenridge AM, Crawford FE, Orme MLE, Rowe PH, Schindler AE(1980e)The pharmacokinetics of a large (3mg) oral dose of ethinylestradiol in women. Contraception 21:145–153PubMedCrossRefGoogle Scholar
  20. Back DJ, Breckenridge AM, MacIver M, Orme MLE, Purba H, Rowe PH(1981)Interaction of ethinylestradiol with ascorbic acid in man. Br Med J 282:1516CrossRefGoogle Scholar
  21. Back DJ, Breckenridge AM, MacIver M, Orme MLE, Purba HS, Rowe PH, Taylor I(1982a)The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans. Br J Clin Pharmacol 13:325–330PubMedGoogle Scholar
  22. Back DJ, Breckenridge AM, Cross KJ, Orme MLE, Thomas E(1982b)An antibiotic interaction with ethynyloestradiol in the rat and rabbit. J Steroid Biochem 16:407–413PubMedCrossRefGoogle Scholar
  23. Back DJ, Barkfeldt JO, Breckenridge AM, Odlind V, Orme MLE, Park BK, Purba H, Tjia J, Victor A(1982c)The enzyme inducing effect of rifampicin in the rhesus monkey and its lack of interaction with oral contraceptive steroids. Contraception 25:307–316PubMedCrossRefGoogle Scholar
  24. Back DJ, Grimmer SFM, Rogers S, Stevenson PJ, Orme MLE(1987)Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. Contraception 36:471–479PubMedCrossRefGoogle Scholar
  25. Back DJ, Orme MLE(1990)Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 18:472–484PubMedCrossRefGoogle Scholar
  26. Back DJ, Houlgrave R, Tjia JF, Ward S, Orme MLE(1991)Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norge stirn ate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid Biochem Molec Bioi 38:219–225CrossRefGoogle Scholar
  27. Back DJ, Orme MLE (1994)Pharmacokinetic drug interactions with oral contraceptives. In: Snow R, Hall P (eds) Steroid Contraceptives and Women’s Response. New York, Plenum Press, pp 103–107CrossRefGoogle Scholar
  28. Baciewicz AM(1985)Oral contraceptive drug interactions. Ther Drug Mon 7: 26–35CrossRefGoogle Scholar
  29. Bailey DG, Arnold JMO, Spence JD(1994)Grapefruit juice and drugs how significant is the interaction?Clin Pharmacokinet 26:91–98PubMedCrossRefGoogle Scholar
  30. Balikian H, Southerland J, Howard CM, Preedy RK(1968)Estrogen metabolism in the male dog. Uptake and disappearance of specific radioactive estrogens in tissues and plasma following estrone-6,7 _3H Administration. Identification of estriol-16a, 17ain tissues and urine. Endocrinology 82:500–510PubMedCrossRefGoogle Scholar
  31. Ball P, Gelbke HP, Haupt 0, Knuppen R(1973)Metabolism of 17a-ethynyl [ 4-14C)oestradiol and [4-14C)mestranol in rat liver slices and interaction between 17 a-ethynyl-2-hydroxyoestradiol and adrenalin. Hoppe-Seyler’s Z Physiol Chern 354:1567–1575CrossRefGoogle Scholar
  32. Ball P, Knuppen R(1974)Metabolism of ethynyloestradiol and mestranol in man and interaction between 2-hydroxy-ethynyloestradiol and epinephrine. Acta Endocr (Kbh) (Suppl) 184:32Google Scholar
  33. Ball SE, Forrester LM, Wolf CR, Back DJ(1990)Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 a-ethinylestradiol Biochem J 267:221–226PubMedGoogle Scholar
  34. Ball P, Knuppen R(1990)Formation, metabolism, and physiologic importance of catecholestrogens. Am J Obstet Gynecol 163:2163–2170PubMedGoogle Scholar
  35. Balogh A, Liewald T, Liewald S, Schroder S, Klinger G, Splinter FC, Hoffmann A(1990)Zum EinfluB eines neuen Gestagens - Dienogest - und seiner Kombination mit Ethinylestradiol auf die Aktivitat von Biotransformationsreaktionen. Zbl Gyn 112:735–746PubMedGoogle Scholar
  36. Balogh A, Irmisch E, Wolf P, Letrari F, Splinter K, Hempel G, Klinger G, Hoffmann A(1991)Zum EinfluB von Levonorgestrel und Ethinylestradiol sowie deren Kombination auf die Aktivitat von Biotransformationsreaktionen. Zbl Gyn 113:1388–1396PubMedGoogle Scholar
  37. Balogh A, Klinger G, Henschel L, Borner A, Vollanth R, Kuhnz W(1995)Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol 48:161–166PubMedCrossRefGoogle Scholar
  38. Banerjee RC, Brazeau P, Saucier R, Husain SM(1973)Effects of norethindrone (17-ethinyl-17 f3-hydroxy-4-estren-3-one) and norgestrel (dl-13f3-ethyl-17 -ethynyl-17 f3-hydroxy-4-gonen-3-one) on the tissue distribution of 3H-estradiol-17f3 in ovariectomized rats. Steroids 21:133–145PubMedCrossRefGoogle Scholar
  39. Baumann A, Fuhrmeister A, Brudny-Kloppel M, Draeger C, Bunte T, Kuhnz W(1996) Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women. Contraception 54:235–242PubMedCrossRefGoogle Scholar
  40. Bawarshi-Nassar RN, Hussain A, Crooks PA(1989)Nasal absorption of 17 aethinylestradiol in the rat. J Pharmacol 41:214–215CrossRefGoogle Scholar
  41. Bhavnani BR, Cecutti A(1993)Metabolic Clearance Rate of Equilin Sulfate and Its Conversion to Plasma Equilin, Conjugated and Unconjugated Equilenin, 1713-Dihydroequilin, and 1713-Dihydroequilenin in Normal Postmenopausal Women and Men Under Steady State Conditions. J Clin Endocrinol Metab 77:1269–1274PubMedCrossRefGoogle Scholar
  42. Bhavnani BR, Cecutti A(1994)Pharmacokinetics of 17f3-Dihydroequilin Sulfate and 17 f3-Dihydroequilin in Normal Postmenopausal Women. J Clin Endocrinol Metab 78:197–204PubMedCrossRefGoogle Scholar
  43. Bhavnani BR, Cecutti A, Wallace D(1994)Metabolism of [3H] 17f3-dihydroequilin and [3H] 17f3-dihydroequilin sulfate in normal postmenopausal women. Steroids 59:389–394PubMedCrossRefGoogle Scholar
  44. Beach VL, Steinetz BG, Giannina T, Meli A(1967)Fate of orally administered quinestrol and ethinyl estradiol in rabbits. Int J Fertil 12:148–154PubMedGoogle Scholar
  45. Berthou F, Dreano Y(1993)High-performance liquid chromatographic analysis of tamoxifen, toremifene and their major human metabolites. J Chromatogr Biomed Appl 616:117–127CrossRefGoogle Scholar
  46. Berthou F, Dreano I, Belloc C, Kangas L, Gautier J-C, Beaune P(1994)Involvement of cytochrome P450 3 A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 47:1883–1895PubMedCrossRefGoogle Scholar
  47. Bird CE, Clark AF(1973)Metabolic clearance rates and metabolism of mestranol and ethynylestradiol in normal young women. J Clin Endocr Metab 36:296–302PubMedCrossRefGoogle Scholar
  48. Bocker R, Kleingeist B, Eichhorn M, Lepper H(1991)In vitro interaction of contraceptive steroids with human liver cytochrome P-450 enzymes. Adv Contraception 7:140–148Google Scholar
  49. Bocker R, Lepper H(1991)Mechanism-based inhibition of human liver cytochrome P-450 by several synthetic steroids. Naunyn-Schmiedeberg’s Arch Pharmacol (Suppl) 343:R13Google Scholar
  50. Boekenoogen SJ, Szefier SJ, Jusko WJ(1983)Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab 56:702–709PubMedCrossRefGoogle Scholar
  51. Bollengier WE, Eisenfeld AJ, Gardner WU(1972)Accumulation of 3H-estradiol in testes and pituitary glands of mice of strains differing in susceptibility to testicular interstitial cell and pituitary tumors after prolonged estrogen treatment. J Natl Cancer Inst 49:847–852PubMedGoogle Scholar
  52. Bolt HM, Remmer H(1972a)The accumulation of mestranol and ethynyloestradiol metabolites in the organism. Xenobiotica 2:489–498PubMedCrossRefGoogle Scholar
  53. Bolt HM, Remmer H(1972b)Retention, metabolism and elimination of 17a-ethynylestradiol-3-methyl ether (mestranol). Xenobiotica 2:77–88PubMedCrossRefGoogle Scholar
  54. Bolt HM, Kappus H, Remmer H(1973)Studies on the metabolism of ethynylestradiol in vitro and in vivo: the significance of 2-hydroxylation and the formation of polar products. Xenobiotica 3:773–785PubMedCrossRefGoogle Scholar
  55. Bolt HM, Kappus H and Bolt M(1975)Effect of rifampicin treatment on the metabolism of oestradiol and 17 a-ethinyloestradiol by human liver microsomes. Eur J Clin Pharmacol 8:301–307PubMedCrossRefGoogle Scholar
  56. Bolt HM, Bolt WH(1974)Pharmacokinetics of mestranol in man in relation to its estrogenic activity. Eur J Clin Pharmacol 7:295–305PubMedCrossRefGoogle Scholar
  57. Bolt WH, Kappus H, Bolt HM(1974)Ring A oxidation of 17 a-ethynylestradiol in man. Horm Metab Res 6:432PubMedCrossRefGoogle Scholar
  58. Bolt HM, Bolt M, Kappus H (1977)Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.Acta Endocrinol 85:185–197Google Scholar
  59. Bolt HM(1979)Metabolism of estrogens-natural and synthetic. Pharmacol Ther 4:155–181PubMedCrossRefGoogle Scholar
  60. Borg ML, Gimona A, Renoux A, Douin MJ, Djebbar F, Panisrouzier R (1995) Pharmacokinetics of estradiol and estrone following repeated administration of menorest®, a new estrogen transdermal delivery system, in menopausal women. Clin Drug Invest 10:96–103CrossRefGoogle Scholar
  61. Breitbach GP, Reister C, Droege H, Bastert G (1994)Pharmakokinetik von Droloxifen im Vergleich zu Tamoxifen.Onkologie 17(SuppI1):49–53CrossRefGoogle Scholar
  62. Brewster D, Jones RS, Symons AM (1977)Effects of neomycin on the biliary excretion and enterohepatic circulation of mestranol and 17,B-oestradiol.Biochem Pharmacol 26:943–946PubMedCrossRefGoogle Scholar
  63. Brody SA, Turkes A, Goldzieher JW(1989)Pharmacokinetics of three bioequivalent norethindrone/mestranol-50μ and three norethindrone/ethinyl estradiol-35μ oc formulations: are “low-dose” pills really lower?Contraception 40: 269–284PubMedCrossRefGoogle Scholar
  64. Bourget C, Flood C, Longcope C(1984)Steroid dynamics in the rabbit. Steroids 43:225–233PubMedCrossRefGoogle Scholar
  65. Cargill DI, Steinetz BG, Gosnell E, Beach VL, Mell A, Fujimoto GI, Reynolds BM(1969)Fate of ingested radiolabeled ethynylestradiol and ist 3-cyclopentyl ether in patients with bile fistulas. J Clin Endocr Metab 29:1051–1061PubMedCrossRefGoogle Scholar
  66. Boyd RA, Yang BB, Abel RB, Eldon MA, Sedman AJ, Forgue ST(1996)Pharmacokinetics of a 7 -day 17,B-estradiol transdermal delivery system: Effect of applicationsite and repeated applications on serum concentrations of estradiol and estrone. J Clin Pharmacol 36:998–1005PubMedCrossRefGoogle Scholar
  67. Carlstrom K, Pschera H, Lunell N-O(1988)Serum levels of estrogens, progesterone, FSH and SHBG during simultaneous vaginal administration of 17 f3-oestradiol and progesterone in the pre- and postmenopause. Maturitas 10:307–316PubMedCrossRefGoogle Scholar
  68. Carlstrom K(1996)Low endogenous estrogen levels - analytical problems. Acta Obstet Gynecol Scand (Suppl) 163:11–15Google Scholar
  69. Cassidenti DL, Vijod AG, Vijod MA, Stanczyk FZ, Lobo RA.(1990)Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. Am J Obstet Gynecol 163:1953–1960PubMedGoogle Scholar
  70. Castagnetta LA, Granata OM, Casto ML, Calabro Met al. (1991)Simple approach to measure metabolic pathways of steroids in living cells.J Chromatogr 572:25–39PubMedCrossRefGoogle Scholar
  71. Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano Jp, Maurel P(1989)Metabolism of cyclosporin A. IV. Purification and identification of the rifampicininducible human liver cytochrome P450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily.Drug Metab Disp 17:197–207Google Scholar
  72. Chandrasekaran, A, Osman, M, Adelman, SJ et al. (1996)Determination of 17adihydroequilenin in rat, rabbit and monkey plasma by high-performance liquid chromatography with fiuorimetric detection.J Chromatogr B 676:69–75CrossRefGoogle Scholar
  73. Cook NJ, Read GF(1995)Oestradiol measurement in women on oral hormone replacement therapy: the validity of commercial test kits. Br J Biomed Sci 52:97–101PubMedGoogle Scholar
  74. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M(1990)The interaction of phenytoin and carbamazepine with combined oral contraceptives. Br J Clin Pharmacol 30:892–896PubMedGoogle Scholar
  75. Crewe KH, Ellis SW, Lennard MS, Tucker GT(1997)Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem PharmacoI53:171–178CrossRefGoogle Scholar
  76. D’Arcy PF(1986) Drug interactions with oral contraceptives. Drug Intell Clin Pharmacy 20:353–362Google Scholar
  77. Dehal SS, Kupfer D (1997)CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Re 57:3402–3406Google Scholar
  78. de Hertogh R, Ekka E, Vanderhayden I, Hoet II(1970)Metabolic clearance rates and the interconversion factors of estrone and estradiol-17 f3in the immature and adult female rat. Endocrinology 87:874–880PubMedCrossRefGoogle Scholar
  79. Desta B(1988) Complete separation of nine equine estrogens by high-performance liquid chromatography. J Chromatogr 435:385–390PubMedCrossRefGoogle Scholar
  80. Dibbelt L, Knuppen R, Jutting G, Heimann S, Klipping CO, Parikka-Olexik H(1991)Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combinationoral contraceptives for three months. Contraception 43:1–21PubMedCrossRefGoogle Scholar
  81. DeVos D, Mould G, Stevenson D(1989)The bioavailability of tamoxifen:new findings and their clinical implications. Current Therapeutic Res 46:703–708Google Scholar
  82. DeVos D, Slee PHTJ, Stevenson D, Briggs RJ (1992) Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer, Cancer Chemother PharmacoI31:76–78CrossRefGoogle Scholar
  83. Dusterberg B, Nishino Y(1982) Pharmacokinetic and pharmacological features of oestradiol valerate. Maturitas 4:315–324PubMedCrossRefGoogle Scholar
  84. Dusterberg B, Schmidt-Gollwitzer M, Humpel M(1985) Pharmacokinetics and Biotransformation of estradiol valerate in ovarectomized women. Horm Res 21:145–154PubMedCrossRefGoogle Scholar
  85. Dusterberg B, Kuhne G, Tauber U(1986) Half-lives in plasma and bioavailability of ethinylestradiol in laboratory animals. Drug Res 36:1187–1190Google Scholar
  86. Dyas J, Turkes A, Read GF, Riad-Fahmy D(1981) A radioimmunoassay for ethinyl oestradiol in plasma incorporating an immunosorbent, pre-assay purification procedure. Ann Clin Biochem 18:37–41PubMedGoogle Scholar
  87. Eisenfeld AJ, Gardner WU, vanWagenen G (1971) Radioactive estradiol accumulation in endometriosis of the rhesus monkey. Am J Obstet Gynecol109:124–130PubMedGoogle Scholar
  88. Elger W, Schwarz S, Hedden AM, Reddersen G and Schneider B (1995) Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol BioI 55:395–-403CrossRefGoogle Scholar
  89. Elsaesser F, Stickney K, Foxcroft G(1982) A comparison of metabolic clearance rates of oestradiol-17 βin immature and peripubertal female pigs and possible implications for the onset of puberty. Acta EndocrinollOO:506–512Google Scholar
  90. EI Yazigi A, Legayada E (1997) Direct liquid chromatographic micro-measurement of tamoxifen in plasma of cancer patients. J Chromatogr B 691:457–-462CrossRefGoogle Scholar
  91. Englund D, Heimer G, Johansson EDB(1984) Influence of food on oestriol blood levels. Maturitas 6:71–75PubMedCrossRefGoogle Scholar
  92. Englund DE, Elamsson KB, Johansson EDB(1982) Bioavailability of oestriol. Acta EndocrinoI99:136–140Google Scholar
  93. Englund DE, Johansson ED (1981) Oral versus vaginal absorption in oestradiol in postmenopausal women. Effects of different particles sizes. Ups J med Sci 86:297–307Google Scholar
  94. Englund DE, Victor A, Johansson ED(1981) Pharmacokinetics and pharmacodynamic effects of vaginal oestradiol administration from silas tic rings in postmenopausal women. Maturitas 3:125–133PubMedCrossRefGoogle Scholar
  95. Erdelyi-Toth V, Pap E, Kralovanszky J, Bojti E, Klebovich I (1994) Determination of panomifene in human plasma by high-performance liquid chromatography. J Chromatogr A 668:419–-425PubMedCrossRefGoogle Scholar
  96. Erdelyi-Toth V, Gyergyay F, Szamel I, Pap E, Kralovanszky J, Bojti E, Csorgo M, Drabant S, Klebovich I (1997) Pharmacokinetics of panomifene in healthy volunteers at phase I1a study. Anti-Cancer Drugs 8:603–609PubMedCrossRefGoogle Scholar
  97. Eugster HP, Probst M, Wurgler FE, Sengstag C(1993) Caffeine, estradiol, and progesterone interact with human CYPIA1 and CYPIA2. Evidence from cDNAdirected expression in Saccharomyces cerevisiae. Drug Metab Dispos 21:43–49PubMedGoogle Scholar
  98. Fernandez N, Garcia 11, Diez MJ, Teran MT, Sierra M(1993)Rapid high-performance liquid chromatographic assay of ethynyloestradiol in rabbit plasma. J Chromatogr Biomed Appl 619:143–147CrossRefGoogle Scholar
  99. Fernandez N, Sierra M, Diez MJ, Teran T, Sahagun AM, Garcia 11(1996) Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. Contraception 53:307–312PubMedCrossRefGoogle Scholar
  100. Fernandez N, Sierra M, Diez MJ, Teran T, Pereda P, Garcia 11 (1997) Study of the pharmacokinetic interaction between ethinylestradioi and amoxicillin in rabbits. Contraception 55:47–52PubMedCrossRefGoogle Scholar
  101. Fishman J, Goldberg S, Rosenfeld RS, Zumoff B, Hellman L, Gallagher TF (1969) Intermediates in the transformation of oral estradiol. J Clin Endocrinol Metab 29:41–46PubMedCrossRefGoogle Scholar
  102. Forgue ST, Rudy AC, Knadler MP, Basson RP, Nelson JE, Henry DP, Allerheiligen SR (1996) Raloxifene pharmacokinetics in healthy postmenopausal women. Pharm Res 13 No.9 (Suppl):S429Google Scholar
  103. Fotherby K(1973) Metabolism of synthetic steroids by animals and man. Acta endor (Copenh Suppl) 185:119–147Google Scholar
  104. Fotherby K, Akpoviroro JO, Siekmann L, Breuer H (1981) Measurement of ethynylestradiol by radioimmunoassay and by isotope dilution-mass spectrometry. J Steroid Biochem 14:499–500PubMedCrossRefGoogle Scholar
  105. Fotherby K (1991) Intrasubject variability in the pharmacokinetics of ethynyloestradiol. J Steroid Biochem Molec BioI 38:733–736CrossRefGoogle Scholar
  106. Fournier S, Kuttenn F, de Cicco F, Baudot N, Malet C, Mauvais Jarvis P (1982) Estradiol 17 f3-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. J Clin Endocrinol Metab 55:428–-433PubMedCrossRefGoogle Scholar
  107. Fraser IS, Challis JRG, Thorburn GD (1976) Metabolic clearance rate and production rate of oestradiol in conscious rabbits. J Endocrinol 68:313–320PubMedCrossRefGoogle Scholar
  108. Frey BM, Frey FJ (1985) The effect of altered prednisolone kinetics in patients with the nephrotic syndrome and in women taking oral contraceptive steroids on human mixed lymphocyte cultures. J Clin Endocrinol Metab 60:361–369PubMedCrossRefGoogle Scholar
  109. Fried KM, Wainer IW (1994) Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J Chromatogr B 655:261–268CrossRefGoogle Scholar
  110. Fridriksdottir H, Loftsson T, Gudmundsson JA, Bjarnason GJ, Kjeld M, Thorsteinsson T (1996) Design and in vivo testing of 17 fi-estradiol-HP beta CD sublingual tablets. Pharmazie 51:39–42PubMedGoogle Scholar
  111. Fromson JM, Pearson S, Bramah S (1973a) The metabolism of tamoxifen (ICI 46474) Part I: In laboratory animals. Xenobiotica 3:693–709PubMedCrossRefGoogle Scholar
  112. Fromson JM, Pearson S, Bramah S (1973b) The metabolism of tamoxifen (ICI 46474) Part II: In female patients. Xenobiotica 3:711–714PubMedCrossRefGoogle Scholar
  113. Fuchs WS, Leary WP, van der Meer MJ, Gay S, Witschital K, von Nieciecki A(1996)Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women. Arzneim ForschlDrug Res 46:418–422Google Scholar
  114. Fullerton FR, Greenman DL, Young JF (1987) Influence of a purified diet and route of administration on the metabolism and disposition of estradiol in B6C3F1 mice. Drug Metab Dispos BioI Fate Chern 15:602–607Google Scholar
  115. Gabrielsson J, Wallenbeck I, Larsson G, Birgerson L, Heimer G (1995) New kinetic data on estradiol in light of the vaginal ring concept. Maturitas 22:S35–S39PubMedCrossRefGoogle Scholar
  116. Galbraith RA, Michnovicz 11 (1989) The effects of cimetidine on the oxidative metabolism of estradiol. N Engl J Med 321:269–274PubMedCrossRefGoogle Scholar
  117. Galbraith RA, Michnovicz 11 (1993) Omeprazole Fails to Alter the Cytochrome-P450-Dependent 2-Hydroxylation of Estradiol in Male Volunteers. Pharmacology 47:8–12PubMedCrossRefGoogle Scholar
  118. Ginsburg ES, Mello NK, Mendelson JHet al. (1996) Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA 276:1747–1751PubMedCrossRefGoogle Scholar
  119. Ginsburg ES, Walsh BW, Shea BF, Gao X, Gleason RE, Barbieri RL (1995) The effects of ethanol on the clearance of estradiol in postmenopausal women. Fertil Steril 63:1227–1230PubMedGoogle Scholar
  120. Goebelsmann U, Mashchak A, Mishell DR (1985) Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet GynecoI151:868–877Google Scholar
  121. Goldzieher JW(1989)Pharmacology of contraceptive steroids: a brief review. Am J Obstet Gyneco1160:1260–1264Google Scholar
  122. Goldzieher JW (1990) Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications. Am J Obstet GynecoI163:318–322Google Scholar
  123. Gomez-Benitez J, Sosa-Gonzales A, Diaz-Chico BN (1984) Relations between 3H_ estradiol uptake and receptor content of estrogen responsive tissues of castrated female rats. Revista Espanola de Fisiologia 40:311–318PubMedGoogle Scholar
  124. Goldzieher JW, Brody SA (1990) Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet GynecoI163:2114–2119Google Scholar
  125. Ghosh SK (1988) Production of monoclonal antibodies to estriol and their application in the development of a sensitive nonisotopic immunoassay. Steroids 52:1–14PubMedCrossRefGoogle Scholar
  126. Grill HJ, Pollow K (1991) Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. Am J Clin Oncol14 (SuppI2):S21–S29CrossRefGoogle Scholar
  127. Grimmer SFM, Back DJ, Orme MLE, Cowie A, Gilmore I, Tjia J (1986) The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. Contraception 33:51–59PubMedCrossRefGoogle Scholar
  128. Guengerich FP (1988) Oxidation of 17a-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 33:500–508PubMedGoogle Scholar
  129. Guengerich FP (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chern Res Toxicol 3:363–371CrossRefGoogle Scholar
  130. Gupta RC, Nityanand S, Asthana OP, Lal J (1996) Pharmacokinetics of centchroman in nursing women and passage into breast milk. Clin Drug Invest 11:305–309CrossRefGoogle Scholar
  131. Gustavson LE, Legler UF, Benet LZ (1986) Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 62:234–-237PubMedCrossRefGoogle Scholar
  132. Haaf H, Metzler M, Li 11 (1988) Influence of a-naphthoflavone on the metabolism and binding of ethinylestradiol in male syrian hamster liver microsomes: possible role in hepatocarcinogenesis. Cancer Res 48:5460–5465PubMedGoogle Scholar
  133. Hammerstein J, Daume E, Simon A, Winkler UH, Schindler AE, Back DJ, Ward S, Neiss A (1993) Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6f3-hydroxycortisol. Contraception 47:263–281PubMedCrossRefGoogle Scholar
  134. Han X, Liehr JG(1992)Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52:1360–1363PubMedGoogle Scholar
  135. Harris RZ, Tsunoda SM, Mroczkowski P, Wong H, Benet LZ (1996) The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Parmacol Ther 59:429–435CrossRefGoogle Scholar
  136. Hasman M, Rattel B, Loser R(1994)Preclinical data for droloxifene. Cancer Lett 84:101–116CrossRefGoogle Scholar
  137. Heffner LJ (1976) 3H-estradiol uptake and retention by target tissues of light-sterilized rats. Neuroendocrin 20:319–327CrossRefGoogle Scholar
  138. Heimer GM (1987) Estriol in the postmenopause. Acta Obstet Gynecol Scand (Suppl) 139:1–23CrossRefGoogle Scholar
  139. Heimer GM, Englund DE (1984) Enterohepatic recirculation of oestriol studied in cholecystectomized and non-cholecystectomized menopausal women. Upsala J Med Sci 89:107–115PubMedCrossRefGoogle Scholar
  140. Heimer GM, Englund DE (1986a) Enterohepatic recirculation of oestriol: inhibition by activated charcoal. Acta EndocrinoI113:93–95Google Scholar
  141. Heimer GM, Englund DE (1986b) Plasma oestriol following vaginal administration: morning versus evening insertion and influence of food. Maturitas 8:239–243PubMedCrossRefGoogle Scholar
  142. Heithecker R, Aedo AR, Landgren BM, Cekan SZ (1991) Plasma estriol levels after intramuscular injection of estriol and two of its esters. Horm Res 35:234–238PubMedCrossRefGoogle Scholar
  143. Hellriegel ET, Matwyshyn GA, Fei P, Dragnev KH, Nims RW, Lubet RA, Kong A-NT (1996) Regulation of gene expression of various phase I and phase II drug-metabolizing enzymes by tamoxifen in rat liver. Biochem PharmacoI52:1561–1568CrossRefGoogle Scholar
  144. Helton ED, Williams EC, Goldzieher JW (1977) Oxidative metabolism and deethynylation of 17 a-ethynyestradiol by baboon liver micro somes. Steroids 30:71–83PubMedCrossRefGoogle Scholar
  145. Hembree WC, Bardin CW, Lipsett MB (1969) A study of estrogen metabolic clearance rates and transfer factors. J Clin Invest 48:1809–1819PubMedCrossRefGoogle Scholar
  146. Henderson KM, Camberis M, Hardie AH (1995) Evaluation of antibody- and antigencoated enzymeimmunoassays for measuring oestrone-3-glucuronide concentratios in urine. Clin Chim Acta 243:191–203PubMedCrossRefGoogle Scholar
  147. Hermens WA, Belder CW, Merkus JM, Hooymans PM, Verhoef J, Merkus FW (1991) Intranasal estradiol administration to oophorectomized women. Eur J Obstet Gynecol Reprod Bioi 40:35–41CrossRefGoogle Scholar
  148. Herz R, Koelz H, Haemmerli U, Benes I, Blum AL (1978) Inhibition of hepatic de methylation of aminopyrine by oral contraceptive steroids in humans. Eur J Clin Invest 8:27–30PubMedCrossRefGoogle Scholar
  149. Hirai S, Hussain A, Haddadin M, Smith RB (1981) First-pass metabolism of ethinyl estradiol in dogs and rats. J Pharmac Sci 70:403–406CrossRefGoogle Scholar
  150. Holleran WM, Gharbo SA, DeGregorio MW (1987) Quantitation of toremifene and its major metabolites in human plasma by high performance liquid chromatography following fluorescent activation. Anal Lett 20:871–879CrossRefGoogle Scholar
  151. Hoon TJ, Dawood MY, Khandawood FS, Ramos J, Batenhorst RL (1993) Bioequivalence of a f3-Hydroxypropyl-f3-Cyclodextrin Complex in Postmenopausal Women. J Clin PharmacoI33:1116–1121Google Scholar
  152. Hu S, He Q, Zhao Z (1992)Determination of trace amounts of estriol and estradiol by adsorptive cathodic stripping voltammetry. Analyst 117:181–184PubMedCrossRefGoogle Scholar
  153. Htimpel M, Nieuweboer B, Wendt H, Speck U(1979)Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women. Contraception 19:421–432CrossRefGoogle Scholar
  154. Htimpel M, Tauber U, Kuhnz W, Pfeffer M, Brill K, Heithecker R, Louton T, Steinberg B(1990)Comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives. Horm Res 33:35–39Google Scholar
  155. Hussain MA, Aungst BJ, Shefter E (1988) Prodrugs for improved oral ,B-estradiol bioavailability. Pharm Res 5:44PubMedCrossRefGoogle Scholar
  156. Iida K, Imai A, Tamaya T (1991) Estriol binding in uterine corpus cancer and in normal uterine tissues. Gen Pharmacol 22:491–493PubMedGoogle Scholar
  157. Jehan Q, Srivasta S, Akhlaq M ETAL Etal. (1982) Kinetics and distribution and retention of 3H -oestradiol-17 ,Bin rat tissues: A comparative study with free oestradiol and after its incorporation into liposomes.Endokrinologie 80:8–12PubMedGoogle Scholar
  158. Jensen RT, Collen MJ, Pandol SJet al. (1983) Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 308:883–887PubMedCrossRefGoogle Scholar
  159. Jochemsen R, Van der Graaff M, Boeijinga JK, Breimer DD (1982) Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam.Br J Clin Pharmacol 13:319–324PubMedGoogle Scholar
  160. Johnston A (1996) Estrogens - pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation - Estring. Acta Obstet Gynecol Scand (Suppl)163:16–25Google Scholar
  161. Joshi JV, Joshi UM, Sankolli GM, Gupta K, Rao AP, Hazari K, Sheth UK, Saxena BN (1980) A study of interaction of a low-dose combination oral contraceptive with anti-tubercular drugs. Contraception 22:643–652PubMedCrossRefGoogle Scholar
  162. Jordan CV (1982) Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat 2:123–138PubMedCrossRefGoogle Scholar
  163. Jung-Hoffmann C, Kuhl H (1989) Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives. Contraception 40:299–312PubMedCrossRefGoogle Scholar
  164. Kall MA, Vang 0, Clausen J (1996) Effects of dietary broccoli on human in vivo drug metabolizing enzymes: Evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis 17:793–799PubMedCrossRefGoogle Scholar
  165. Kalund-Jensen, H, Myren, CJ (1984) Vaginal absorption of oestradiol and progesterone. Maturitas 6:359–367PubMedCrossRefGoogle Scholar
  166. Kamyab S, Fotherby K (1969) Metabolism of 4-14C-ethynyl oestradiol in women. Nature 221:360–361CrossRefGoogle Scholar
  167. Katayama M, Taniguchi H (1993) Determination of Estrogens in Plasma by HighPerformance Liquid Chromatography After Pre-Column Derivatization with 2-(4-carboxyphenyl)-5,6-dimethylbenzimidazole. J Chromatogr 616:317–322PubMedCrossRefGoogle Scholar
  168. Kaufmann JM, Thiery M, Vermeulen A (1981) Plasma levels of ethinylestradiol (EE) during cyclic treatment with combined oral contraceptives. Contraception 24:589–602CrossRefGoogle Scholar
  169. Kazama N, Longcope C (1972) Metabolism of estrone and estradiol-17,B in sheep. Endocrinology 91:1450–1454PubMedCrossRefGoogle Scholar
  170. Kemp JV, Adam HK, Wakeling AE, Slater R (1983) Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol 32:2045–2052PubMedCrossRefGoogle Scholar
  171. Kerlan V, Dreano Y, Bercovici JP, Beaune PH, Floch HH, Berthou F (1992) Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem Pharmacol44:1745–1756PubMedCrossRefGoogle Scholar
  172. Kholkute SD, Kumar TCA, Puri CP (1987) Pharmacokinetic and pharmacodynamic studies on estradiol-17,B administered sublingually or intramuscularly to adult male marmosets. Adv Contra Delv Sys 3:195–204Google Scholar
  173. Klein KO, Baron J, Colli MJ, Mcdonnell DP, Cutler GB (1994) Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 94:2475–2480PubMedCrossRefGoogle Scholar
  174. Knadler MP, Lantz RJ, Gillespie TA, Allerheiligen SRB, Henry DP (1995) The disposition and metabolism of 14C-Iabeled raloxifene in humans. Pharm-Res 12 No.9 (Suppl):S372Google Scholar
  175. Kohler PC, Hamm JT, Wiebe VJ, DeGregorio MW, Shemano I, Tormey DC (1990) Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer. Breast Cancer Res Treat 16 (Suppl):S19–S26CrossRefGoogle Scholar
  176. Kuhnz W, Putz B (1989) Pharmacokinetic interpretation of toxicity tests in rats treated with oestradiol valerate in the diet. Pharmacol Toxicol 65:217–222PubMedCrossRefGoogle Scholar
  177. Kuhnz W, Hiimpel M, Schiitt B, Louton T, Steinberg B, Gansau C (1990a) Relative bioavailability of ethinyl estradiol from two different oral contraceptive formulations after single oral administration to 18 women in an intraindividual cross-over design. Horm Res 33:40–44PubMedCrossRefGoogle Scholar
  178. Kuhnz W, Pfeffer M, AI-Yacoub G (1990b) Protein binding ofthe contraceptive steroids gestodene, 3-ketodesogestrel and ethinylestradiol. J Steroid Biochem 35:313–318PubMedCrossRefGoogle Scholar
  179. Kuhnz W, Back DJ, Power J, Schiitt B, Louton T (1991) Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of three months with two low-dose oral contraceptives in an intraindividual cross-over design. Horm Res 36:63–69PubMedCrossRefGoogle Scholar
  180. Kuhnz W, Gansau C, Fuhrmeister A (1992a) Pharmacokinetics of gestodene in 12 women who received a single oral dose of 0.075 mg gestodene and, after a washout phase, the same dose during a treatment cycle. Contraception 46:29–40PubMedCrossRefGoogle Scholar
  181. Kuhnz W, AI-Yacoub G, Fuhrmeister A (1992b) Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a wash-out phase, the same dose during a treatment cycle. Contraception 46:443–454PubMedCrossRefGoogle Scholar
  182. Kuhnz W, Gansau C, Mahler M (1993a) Pharmacokinetics of Estradiol, Free and Total Estrone, in Young Women Following Single Intravenous and Oral Administration of 17 f3-Estradiol. Arzneimittelforsch 43-2:966–973PubMedGoogle Scholar
  183. Kuhnz W, Louton T, Back DJ, Michaelis K (1993b) Radioimmunological analysis of ethinylestradiol in human serum. Validation of the method and comparison with a gas chromatographic/mass spectrometric assay. Arzneim Forsch/Drug Res 43:16–21Google Scholar
  184. Kuhnz W, Baumann A, Staks T, Dibbelt L, Knuppen R, Jiitting G (1993c) Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. Contraception 48:303–322PubMedCrossRefGoogle Scholar
  185. Kuhnz W, Blode H (1994) Pharmacokinetics of selected contraceptive steroids in various animal species. In:Goldzieher J(ed)Pharmacology of the contraceptive steroids.Raven Press, New York, pp 41–51Google Scholar
  186. Kuhnz W, Staks T, Jiitting G (1994) Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. Contraception 50:563–579PubMedCrossRefGoogle Scholar
  187. Kuhnz W, Hiimpel M, Biere H, Gross D (1996) Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women. Eur J Clin PharmacoI50:231–235CrossRefGoogle Scholar
  188. Kulkarni BD(1970)Metabolism of [14C)ethynylestradiol in the baboon. J Endocrinol 48:91–98PubMedCrossRefGoogle Scholar
  189. Kulkarni BD, Goldzieher JW (1970) Urinary excretion pattern and fractionation of radioactivity after injection of 4-14C-mestranol in women. Contraception 1:131–136CrossRefGoogle Scholar
  190. Kulkarni BD (1976) Steroid contraceptives in non-human primates (I). Metabolic fatew of synthetic estrogens in the baboon before exposure to oral contraceptives. Contraception 14:611–623PubMedCrossRefGoogle Scholar
  191. Kvorning I, Christensen MS (1981) Bioavailability of four oestradiol suspensions with different particle-sizes - in vivo/in vitro correlation. Drug Dev Ind Pharm 7:289–303CrossRefGoogle Scholar
  192. Lal J, Paliwal JK, Grover PK, Gupta RC (1994) Simultaneous liquid chromatographic determination of centchroman and its 7 -demethylated metabolite in serum and milk. J Chromatogr B 658:193–197CrossRefGoogle Scholar
  193. Lal J, Asthana OP, Nityanand S, Gupta RC (1995) Pharmacokinetics of centchroman in healthy female subjects after oral administration. Contraception 52:297–300PubMedCrossRefGoogle Scholar
  194. Lal J, Nityanand S, Asthana OP, Gupta RC (1996) Comparative bioavailability of two commercial centchroman tablets in healthy female sUbjects. Indian J Pharmacol 28:32–34Google Scholar
  195. Lantz RJ, Knadler MP (1993) HPLC Determination of raloxifene before and after hydrolysis of human plasma. Pharm Res 10 No. 10 (Suppl):S50Google Scholar
  196. Lamer JM, Hochberg RB (1985) The clearance and metabolism of estradiol and estradiol-17-esters in the rat. Endocrinology 117:1209–1214CrossRefGoogle Scholar
  197. Lee GJL, Oyang MH, Bautista J, Kushinsky S (1987) Determination of ethinylestradiol and norethindrone in a single specimen of plasma by automated highperformance liquid chromatography and subsequent radioimmunoassay. J Liquid Chromatogr 10:2305–2318CrossRefGoogle Scholar
  198. Lee YS, Lorenzo BJ, Koufis T, Reidenberg MM (1996) Grapefruit juice and its flavonoids inhibit 11j3-hydroxysteroid dehydrogenase. Clin Pharmacol Ther 59:62–71PubMedCrossRefGoogle Scholar
  199. Leroux Y, Borg ML, Sibille M et a1. (1995) Bioavailability study of Menorest®, a new estrogen trans dermal delivery system, compared with a transdermal reservoir system. Clin Drug Invest 10:172–178CrossRefGoogle Scholar
  200. Levrant SG, Barnes RB (1994) Pharmacology of estrogens. In:Lobo RA (ed) Treatment of the postmenopausal woman. Basic and clinical aspects.Raven Press, New York, pp 57–68Google Scholar
  201. Lichtenberg V, Chulte-Baukloh A, Lindner C and Braendle W (1992) Die Bestimmung von 17 -j3-0stradiol (E2) im Serum von Frauen unter einer Ostrogen-Substitutionstherapie liefert diskrepante Ergebnisse mit verschiedenen Immunoassay-Kits. Lab Med 16:412–-418Google Scholar
  202. Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM (1990) Decreased serum concentrations of tamoxifen and ist metabolites induced by amino glutethimide. Cancer Res 50:5851–5857PubMedGoogle Scholar
  203. Lien EA, Solheim E, Ueland PM (1991a) Distribution of tamoxifen and ist metabolites in rat and human tissues during steady-state treatment. Cancer Res 51:4837–4844PubMedGoogle Scholar
  204. Lien EA, Wester K, Lonning PE, Solheim E, Ueland PM (1991b) Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 63:641–645PubMedCrossRefGoogle Scholar
  205. Lien EA, Anker G, Lonning PE, Ueland PM (1995a) Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Ther Drug Monit 17:259–265PubMedCrossRefGoogle Scholar
  206. Lien EA, Anker G, Ueland PM (1995b) Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer. J Steroid Biochem Mol Bioi 55:229–231CrossRefGoogle Scholar
  207. Longcope C, Williams KIH (1977) Ethynylestradiol and mestranol: their pharmacodynamics and effects on natural estrogens. In:Garattini S, Berendes HW (eds)Pharmacology of steroid contraceptive drugs.Raven Press, New York, pp 89–98Google Scholar
  208. Lim CK, Chow LCL, Yuan Z-X, Smith LL (1993) High performance liquid chromatography of tamoxifen and metabolites in plasma and tissues. Biomed Chromatogr 7:311–314PubMedCrossRefGoogle Scholar
  209. Lim CK, Yuan Z-X, Ying K-C, Smith LL (1994a) High performance liquid chromatography of toremifene and metabolites. J Liquid Chromatogr 17:1773–1783CrossRefGoogle Scholar
  210. Lim CK, Yuan Z-X, Lamb JH, White INH, DeMatteis F, Smith LL (1994b) A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 15:589–593PubMedCrossRefGoogle Scholar
  211. Lim CK, Yuan Z-X, Jones RM, White INH, Smith LL (1997) Identification and mechanism of formation of potentially genotoxic metabolites of tamoxifen: study by LC-MS/MS. J Pharmaceut Biomed Anal 15:1335–1342CrossRefGoogle Scholar
  212. Lindstrom TD, Whitacker NG, Whitacker GW (1984) Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica 14:841–847PubMedCrossRefGoogle Scholar
  213. Littleton GK, Anderson RR (1972) Characterization of 17 f3-estradiol-3H single injection disappearance curves in rat plasma and red cells (36602). Proc Soc Exp Bioi Med 140:1015–1020Google Scholar
  214. Lobo RA, Brenner P, Mishell DR, Jr (1983) Metabolic parameters and steroid levels in postmenopausal women receiving lower doses of natural estrogen replacement. Obstet Gynecol 62:94–98PubMedGoogle Scholar
  215. Lobo RA, Cassidenti DL(1992)Pharmacokinetics of oral 17 f3-estradiol. J Reprod Med 37:77–84PubMedGoogle Scholar
  216. Lobo RA, Ettinger B, Hutchinson KA, Knopp RH, Lindsay R, Nachtigall LE, Santoro N, Studd J, Hutchinson KA et al. (1996) Estrogen replacement. The evolving role of transdermal delivery. J Reprod Med 41:781–796Google Scholar
  217. Lodwick R, McConkey B, Brown AM (1987) Life threatening interaction between tamoxifen and warfarin. Br Med J 295:141CrossRefGoogle Scholar
  218. Lokind KB, Lorenzen FH, Bundgaard H (1991) Oral Bioavailability of 17f3-Estradiol and Various Ester Prodrugs in the Rat. Int J Pharmaceut 76:177–182CrossRefGoogle Scholar
  219. Longcope C, Flood C, Tast J (1994) The metabolism of estrone sulfate in the female rhesus monkey. Steroids 59:270–273PubMedCrossRefGoogle Scholar
  220. Longcope C, Gorbach S, Goldin Bet al. (1985) The metabolism of estradiol; oral compared to intravenous administration.J Steroid Biochem 23:1065–1070PubMedCrossRefGoogle Scholar
  221. Longcope C, Gorbach S, Goldin Bet al. (1987) The effect of a low fat diet on estrogen metabolism. J Clin Endocrinol Metab 64:1246PubMedCrossRefGoogle Scholar
  222. Longcope C, Williams KIH (1974) The metabolism of estrogens in normal women after pulse injections of 3H-estradiol and 3H-estrone. J Clin Endocrinol Metab 38:602–607PubMedCrossRefGoogle Scholar
  223. Lonning PE, Ekse D (1995) A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. J Steroid Biochem Mol Bioi 55:409–412CrossRefGoogle Scholar
  224. Lonning PE, Kvinnsland S, Thorsen T, Ekse D (1986) Aminoglutethimide as an inducer of microsomal enzymes. Part 2: Endocrine aspects.Breast Cancer Res Treat 7 (Suppl):S77–S82PubMedCrossRefGoogle Scholar
  225. Lonning PE, Kvinnsland S, Thorsen T, Ueland PM (1987) Alterations in the metabolism of estrogens during treatment with aminoglutethimide in breast cancer patients. Clin Pharmacokinet 13:393–406PubMedCrossRefGoogle Scholar
  226. Lonning PE, Lien EA, Lundgren S, Kvinnsland S (1992) Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22:327–358PubMedCrossRefGoogle Scholar
  227. Lonning PE, Lien EA (1993) Pharmacokinetics of anti-endrocrine agents.In:Workman P, Graham MA(guest eds)Cancer Surveys, Volume 17, Pharmacokinetics and cancer chemotherapy.Cold Spring Harbour Laboratory Press, pp 343–370Google Scholar
  228. Loock W, Nau H, Schmidt Gollwitzer M, Dvorchik BH (1988) Pregnancy-specific changes of antipyrine pharmacokinetics correlate inversely with changes of estradiol/ progesterone plasma concentration ratios. J Clin Pharmacol 28:216–221PubMedGoogle Scholar
  229. Lorkowski G, Lucker PW, Petersen G, Schnitzler M, Wetzelsberger N (1994) Bioequivalence of two commercially available tamoxifen tablet formulations in healthy male volunteers. Meth Find Exp Clin Pharmacol 16:443–447Google Scholar
  230. Luttge WG, Whalen RE (1972) The accumulation, retention and interaction of oestradiol and oestrone in central neural and peripheral tissues of gonadectomized female rats. J Endocrinol 52:379–395PubMedCrossRefGoogle Scholar
  231. MacCallum J, Cummings J, Dixon JM, Miller WR (1996) Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma. JChromatogr B 678:317–323CrossRefGoogle Scholar
  232. Mackinnon M, Sutherland E, Simon FR (1977) Effects of ethinyl estradiol on hepatic microsomal proteins and the turnover of cytochrome P-450. 1 Lab Clin Med 90:1096–1106Google Scholar
  233. Maggs LL, Grabowski PS, Rose ME, Park BK(1982)The biotransformation of 17aethynyl [ 3H]estradiol in the rat: irreversible binding and biliary metabolites. Xenobiotica 12:657–668PubMedCrossRefGoogle Scholar
  234. Maggs LL, Grimmer SFM, Orme MLE, Breckenridge AM, Park BK (1983a) The biliary and urinary metabolites of 3H-17a-ethynylestradiol in women. Xenobiotica 13:421–431PubMedCrossRefGoogle Scholar
  235. Maggs LL, Grabowski PS, Park BK (1983b) The enterohepatic circulation of the metabolites of 17 a-ethynyWH]estradiol in the rat. Xenobiotica 13:619–626PubMedCrossRefGoogle Scholar
  236. Maggs LL, Park BK (1985) A comparative study of biliary and urinary 2-hydroxylated metabolites of [6,7-3H] 17 a-ethynylestradiol in women. Contraception 32:173–182PubMedCrossRefGoogle Scholar
  237. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D (1993a) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen I.Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos 21:645–656PubMedGoogle Scholar
  238. Mani C, Hodgson E, Kupfer D (1993b) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen II. Flavin-containing monooxygenase-mediated Noxidation. Drug Metab Dispos 21:657–661Google Scholar
  239. Mani C, Kupfer D (1991) Cytochrome P450 mediated action and irreversible binding of the anti estrogen tamoxifen to proteins in rat and human liver: possible involvement of the flavin-containing monooxygenases in tamoxifen activation. Cancer Res 51:6052–6058PubMedGoogle Scholar
  240. Martinsen A, Gynther 1 (1996) Liquid chromatography-thermospray mass spectrometry of toremifene and its derivatives. 1 Chromatogr A 724:358–363CrossRefGoogle Scholar
  241. Martucci CP, Fishman 1 (1993) P450 Enzymes of Estrogen Metabolism. Pharmacol Ther 57:237–257PubMedCrossRefGoogle Scholar
  242. Marynick SP, Havens WW, Ebert MHet al. (1976) Studies on the transfer of steroid hormones across the blood-cerebrospinal fluid barrier in the rhesus monkey. Endocrinology 99:400–405PubMedCrossRefGoogle Scholar
  243. MeffinPl, Wing LMH, Sallustio BC, Brooks PM (1984) Alterations in prednisolone disposition as a result of oral contraceptive use and dose. Br 1 Clin Pharmac 17:655–664Google Scholar
  244. Mattsson LA, Cullberg G (1983) Vaginal absorption of two estriol preparations. Acta Obstet Gynecol Scand 62:393–396PubMedCrossRefGoogle Scholar
  245. Meltzer NM, Stang P, Sternson LA (1984) Influence of tamoxifen and its N-desmethyl and 4-hydroxy metabolites on rat liver microsomal enzymes. Biochem Pharmacol 33:115–123PubMedCrossRefGoogle Scholar
  246. Meyer FP, Walther H, Canzler E, Giers H (1989) EinfluB der oralen Kontrazeptiva MinisistonlTrisiston auf die Pharmakokinetik von Coffein - ein intraindividueller Langzeitversuch. Z Klin Mrd 44:239–240Google Scholar
  247. Middeke M, Remien C, Lohmtiller G, Holzgreve H, Zollner N (1986) Interaction between tamoxifen and digitoxin? Klin Wschr 64:1211CrossRefGoogle Scholar
  248. Mikkelsen AL, Borggaard B, Lebech PE (1996) Results of serial measurement of estradiol in serum with six different methods during ovarian stimulation. Gynecol Obstet Invest 41:35–40PubMedCrossRefGoogle Scholar
  249. Mills TM, Lin TJ, Hernandez-Ayup S, Greenblatt RB, Ellegood 10, Mahesh VB (1974) The metabolic clearance rate and urinary excretion of oral contraceptive drugs. Am 1 Obstet GynecoI120:773–778Google Scholar
  250. Muller P, Botta L, Ezzet F (1996) Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system.Eur 1 Clin Pharmacol 51:327–330CrossRefGoogle Scholar
  251. Murugesan K, Vij U, Lal B, Farooq A(1989)Effect of progestins, estradiol, and coenzymes NAD and NADPH on the interconversion of estradiol and estrone in rabbit uterus in vitro. Steroids 53:695–712PubMedCrossRefGoogle Scholar
  252. Musey PI, Kirdani RY, Bhanalaph T, Sandberg AA (1973) Estriol metabolism in the baboon: Analysis of urinary and biliary metabolites. Steroids 22:795–817PubMedCrossRefGoogle Scholar
  253. Nash HA, Brache V, Alvarez-Sanchez F, Jackanicz TM, Harmon TM (1997) Estradiol delivery by vaginal rings: Potential for hormone replacement therapy. Maturitas 26: 27–33PubMedCrossRefGoogle Scholar
  254. Newburger J, Castracane VD, Moore PH, Williams MC, Goldzieher JW (1983) The pharmacokinetics and metabolism of ethynyl estradiol and its three sulfates in the baboon. Am J Obstet GynecoI146:80–87Google Scholar
  255. Newburger J, Goldzieher JW (1985) Pharmacokinetics of ethynyl estradiol: a current view. Contraception 32:33–44PubMedCrossRefGoogle Scholar
  256. Ni L, Allerheiligen SRB, Basson R, Knadler MP, Latz J, Geiser J, Lantz R, Rash J, Henry DP (1996) Pharmacokinetics of raloxifene in men and postmenopausal women volunteers: Pharm Res 13 No.9 (Suppl):S430Google Scholar
  257. Nickerson DF, Tess DA, Toler SM (1997) First-pass metabolism and biliary recirculation of droloxifene in the female Sprague-Dawley rat: Xenobiotica 27:257–264PubMedCrossRefGoogle Scholar
  258. Noma J, Hayashi N; Sekiba K (1991) Automated direct high-performance liquid chromatographic assay for estetrol, estriol, cortisone and cortisole in serum and amniotic fluid. J Chromatogr A 568:35–44Google Scholar
  259. Notelovitz M, Tjapkes J, Ware M (1981) Interaction between estrogen and dilantin in a menopausal women. N Engl J Med 304:788PubMedCrossRefGoogle Scholar
  260. Nozaki 0, Ohba Y, Imai K (1988) Determination of serum estradiol by normal-phase high-performance liquid chromatography with peroxyoxalate chemiluminescence detection. Anal Chim Acta 205:255–260CrossRefGoogle Scholar
  261. Nuwaysir EF, Dragan YP, Jefcoate CR, Jordan VC, Pitot HC (1995) Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. Cancer Res 55:1780–1786PubMedGoogle Scholar
  262. O’Connell, MB (1995) Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 35:S18–S24Google Scholar
  263. Orme MLE, Back DJ, Ball S (1989) Interindividual variation in the metabolism of ethynylestradiol. Pharmacol Ther 43:251–260PubMedCrossRefGoogle Scholar
  264. Oriowo MA, Landgren BM, Stenstrom B, Diczfalusy E (1980) A comparison of the pharmacokinetic properties of three estradiol esters. Contraception 21:415–424PubMedCrossRefGoogle Scholar
  265. Orme M, Back DJ, Ward S, Green S (1991) The pharmacokinetics of ethinylestradiol in the presence and absence of gestodene and desogestrel. Contraception 43:305–316PubMedCrossRefGoogle Scholar
  266. Ortiz de Montellano PR, Kunze K, Yost GS, Mico BA (1979) Self-catalized destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme. Proc Nat’l Acad Sci USA 76:746–749CrossRefGoogle Scholar
  267. Pazzucconi F, Malavasi B, Galli G, Franceschini G, Calabresi L, Sirtori CR (1991) Inhibition of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel. Clin Pharmacol Ther 49:278–284PubMedCrossRefGoogle Scholar
  268. Paliwal JK, Gupta RC, Grover PK,Asthana OP, Srivastava JS, Nityanand S (1989) High performance liquid chromatographic (HPLC) determination of centchroman in human serum and application to single-dose pharmacokinetics. Pharmaceut Res 6:1048–1051CrossRefGoogle Scholar
  269. Paliwal JK, Gupta RC (1996) Tissue distribution and pharmacokinetics of centchroman. A new nonsteroidal postcoital contraceptive agent and ist 7-desmethyl metabolite in female rats after single oral dose. Drug Metab and Dispos 24:148–155Google Scholar
  270. Patel J, Katovich MJ, Sloan KB, Curry SH, Prankerd RJ (1995) A prodrug approach to increasing the oral potency of a phenolic drug. 2. pharmacodynamics and preliminary bioavailability of an orally administered o(imidomethyl) derivative of 17f3-estradiol. J Pharm Sci 84:174–178PubMedCrossRefGoogle Scholar
  271. Peden NR, Cargill J, Browning MCet al. (1979) Male sexual dysfunction during treatment with cimetidine.Br Med J 1:659PubMedCrossRefGoogle Scholar
  272. Peyrade F, Frenay M, Etienne M-C, Ruch F, Guillemare C, Francois E, Namer M, Ferrero J-M, Milano G (1996) Age-related difference in tamoxifen disposition. Clin Pharmacol Ther 59:401–410PubMedCrossRefGoogle Scholar
  273. Podesta A, Smith CJ, Villani C, Montagnoli G (1996) Shared reaction in solid-phase immunoassay for estriol determination. Steroids 61:622–626PubMedCrossRefGoogle Scholar
  274. Potischman N, Falk RT, Laiming VA, Siiteri PK, Hoover RN (1994) Reproducibility of laboratory assays for steroid hormones and sex hormone-binding globulin. Cancer Res 54:5363–5367PubMedGoogle Scholar
  275. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA (1988) Pharmacokinetics and pharmacodynamics of transdermal formulations of estradiol. Munch Med Wochenschr 130:7–14Google Scholar
  276. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW(1997)Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17 f3-estradiol. Obstet Gynecol 89:340–345PubMedCrossRefGoogle Scholar
  277. Pschera H, Hjerpe A, Carlstrom K (1989) Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17 f3 and progesterone in postmenopausal women. Gynecol Obstet Invest 27:204–207PubMedCrossRefGoogle Scholar
  278. Purba HS, Maggs JL, Orme MLE, Back DJ, Park BK (1987) The metabolism of 17aethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmac 23:447–453Google Scholar
  279. Raitano LA, Slikker W, Hill DE, Hadd HE, Cairns T, Helton ED (1981) Ethynyl cleavage of 17a-ethynylestradiol in the rhesus monkey. Drug Metab Disp 9:129–134Google Scholar
  280. Ratna S, Roy SK, Ray S, Kole PL, Salman M, Madhusudan KP, Sircar, KP, Anand N (1986) Centchroman: In vitro metabolism by rat liver homogenate. Drug Develop Res 7:173–178CrossRefGoogle Scholar
  281. Ratna S, Mishra NC, Ray S, Roy SK (1994) Centchroman: tissue distribution and excretion profile in albino rats after oral and intravenous administration. J Basic Appl Biomed 2:31–36Google Scholar
  282. Rauramo L, Pun non en R, Kaihola H-L, Grónroos M (1978) Serum oestriol, oestrone and and oestradiol concentrations during oral oestriol succinate treatment in ovariectomized women. Maturitas 1:71–78PubMedCrossRefGoogle Scholar
  283. Reed MJ, Fotherby K, Steele SJ (1972) Metabolism of ethynyloestradiol in man. J Endocr 55:351–361PubMedCrossRefGoogle Scholar
  284. Reed MJ, Fotherby K(1975)Metabolism of ethynyloestradiol and oestradiol in the guinea-pig. J Steroid Biochem 6:121–125PubMedCrossRefGoogle Scholar
  285. Reed MJ, Fotherby K (1979)Intestinal absorption of synthetic steroids. J Steroid Biochem 11:1107–1112PubMedCrossRefGoogle Scholar
  286. Reed MJ, Lai LC, Ghilchik MW, James VHT (1988) The effects of androgens and cortisol on the in vivo metabolism of oestradiol. J Steroid Biochem 30:489–492PubMedCrossRefGoogle Scholar
  287. Reid AD, Horobin JM, Newman EL, Preece PE (1992) Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients. Breast Cancer Res Treat 22:153–156PubMedCrossRefGoogle Scholar
  288. Ritchie LD, Grant SMT (1989) Tamoxifen-warfarin interaction: the Aberdeen hospitals drug file. Br Med J 298:1253CrossRefGoogle Scholar
  289. Roberts RK, Desmond PV, Wilkinson GR, Schenker S (1979) Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives. Clin Pharmacol Ther 25:826–831PubMedGoogle Scholar
  290. Rogers SM, Back DJ, Orme MLE (1987a) Intestinal metabolism of ethinyloestardiol and paracetamol in vitro: studies using Ussing Chambers. Br J Clin Pharmacol 23:727–734PubMedGoogle Scholar
  291. Rogers SM, Back DJ, Stevenson PJ, Grimmer SFM, Orme MLE (1987b) Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol. Br J Clin Pharmacol 23:721–725PubMedGoogle Scholar
  292. Rohr UD, Nauert C, Ehrly AM (1995) Kinetics of a new patch for transdermal administration of 17 f3-estradiol. Zbl Gynakol 117:531–539Google Scholar
  293. Ruenitz PC, Bai X (1995) Acidic metabolites of tamoxifen. Aspects of formation and fate in the female rat. Drug Metab Dispos 23:993–998Google Scholar
  294. RuoffWL, Dziuk PJ (1994) Absorption and metabolism of estrogens from the stomach and duodenum of pigs. Dom Anim Endocrinol11:197–208CrossRefGoogle Scholar
  295. Sandberg AA, Slaunwhite WR (1957) Studies on phenolic steroids in human subjects. II. The metabolic fate and hepatobiliary-enteric circulation of 14C-estrone and 14C_ estradiol in women. J Clin Invest 36:1266–1278PubMedCrossRefGoogle Scholar
  296. Sanders JM, Burka LT, Shelby MD, Newbold RR, Cunningham ML (1997) Determination of tamoxifen and metabolites in serum by capillary electrophoresis using a nonaqueous buffer system J Chromatogr B 695:181–185CrossRefGoogle Scholar
  297. Sato H, Mochizuki H, Tomita Y, Kanamori T (1996) Enhancement of the sensitivity of a chemiluminescent immunoassay for estradiol based on hapten heterology. Clin Biochem 29:509–513PubMedCrossRefGoogle Scholar
  298. Scavone JM, Greenblatt DJ, Blyden GT (1988) Antipyrine pharmacokinetics in women receiving conjugated estrogens. J Clin Pharmacol 28:463–466PubMedGoogle Scholar
  299. Schiff I, Tulchinsky D, Ryan KJ (1977) Vaginal absorption of estrone and 17 f3-estradiol. Fertil SteriI28:1063–1066Google Scholar
  300. Schiff I, Tulchinsky D, Ryan KJet al. (1980) Plasma estriol and its conjugates following oral and vaginal administration of estriol to postmenopausal women: correlations with gonadotropin levels.Am J Obstet Gynecol138:1137–1141PubMedGoogle Scholar
  301. Schmid SE, Au WYW, Hill DE, Kadlubar FF, Slikker W (1983) Cytochrome P-450-dependent oxidation of the 17 a-ethynyl group of synthetic steroids. Drug Metab Dispos 11:531–536PubMedGoogle Scholar
  302. Schmider J, Greenblatt DJ, von Moltke LL, Karsov D, Vena R, Friedman HL, Shader RI (1997) Biotransformation of mestranol to ethynyl estradiol in vitro: the role of cytochrome P-450 2C9 and metabolic inhibitors. J Clin Pharmacol 37:193–200PubMedGoogle Scholar
  303. Schmidt G, Andersson SB, Nordle 0, Johansson CJ, Gunnarsson PO (1994) Release of 17 f3-oestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation. Gynecol Obstet Invest 38:253–260PubMedCrossRefGoogle Scholar
  304. Schneider J, Kinne D, Fracchia Aet al. (1982) Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 79:3047–3051PubMedCrossRefGoogle Scholar
  305. Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T (1995) Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17 f3-estradiol. Eur J Drug Metab Pharmacokinet 20:219–224PubMedCrossRefGoogle Scholar
  306. Schubert W, Cullberg G, Edgar B, Hedner T (1994) Inhibition of 17 f3-estradiol metabolism by grapefruit juice in ovariectomized women. Maturitas 20:155–163PubMedCrossRefGoogle Scholar
  307. Schubert W, Cullberg G, Hedner T (1993) Pharmacokinetic evaluation of oral 17f3-oestradiol and two different fat soluble analogues in ovariectomized women. Eur J Clin PharmacoI44:563–568CrossRefGoogle Scholar
  308. Schwenk M, Schiemenz C, Del Pino VL, Remmer H (1982) First pass biotransformation of ethinylestradiol in rat small intestine in situ. Naunyn-Schmiedeberg’s Arch Pharmacol 321:223–225CrossRefGoogle Scholar
  309. Scott RT, Ross B, Anderson C, Archer DF (1991) Pharmacokinetics of percutaneous estradiol: A crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 77:758–764PubMedGoogle Scholar
  310. Shenfield GM (1993) Oral contraceptives are drug interactions of clinical significance?Drug Safety 9:21–37PubMedCrossRefGoogle Scholar
  311. Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzales FJ, Gelboin HV (1997) Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 18:207–214PubMedCrossRefGoogle Scholar
  312. Siekmann L, Siekmann A, Breuer H (1980) Measurement by isotope dilution mass spectrometry of 17 a-ethinyl-estradiol-17 f3 and norethisterone in serum of women taking oral contraceptives. Biomed Mass Spectrometry 7:511–514CrossRefGoogle Scholar
  313. Siiteri PK, Murai JT, Hammond GL, Nisker JA, Raymoure WJ, Kuhn RW (1982) The serum transport of steroid hormones. Recent Prog Horm Res 38:457–510PubMedGoogle Scholar
  314. Sipila H, NantO V, Kangas L, Anttila M, Halme T (1988) Binding of toremifene to human serum proteins. Pharmacol Toxicol 63:62—64PubMedCrossRefGoogle Scholar
  315. Sipila H, Kangas L, Vuorilehto L, Kalapudas A, Eloranta M, Sodervall M, Toivola R, Anttila M(1990)Metabolism of toremifene in the rat. J Steroid Biochem 36:211–215PubMedCrossRefGoogle Scholar
  316. Slikker W, Bailey JR, Newport GD, Lipe GW, Hill DE (1982) Placental transfer and metabolism of 17 a-ethynylestradiol-17 {3 and estradiol-17 {3 in the rhesus monkey. J Pharmacol Exp Ther 223:483–489PubMedGoogle Scholar
  317. Slikker W, Lipe GW, Newport GD (1981) High-performance liquid chromatographic analysis of estradiol-17 and metabolites in biological media. J Chromatogr 224:205–219CrossRefGoogle Scholar
  318. Soe L, Wurz GT, Maenpaa JU, Hubbard GB, Cadman TB, Wiebe VJ, Theon AP, DeGregorio MW (1997) Tissue distribution of transdermal toremifene. Cancer Chemother Pharmacol 39:513–520PubMedCrossRefGoogle Scholar
  319. Sotaniemi EA, Anttila MI (1997) Influence of age on toremifene pharmacokinetics. Cancer Chemother PharmacoI40:185–188CrossRefGoogle Scholar
  320. Speck U, Wendt H, Schulze PE, Jentsch D (1976) Bioavailability and pharmacokinetics of cyproterone acetate-14C and ethinyloestradiol-3H after oral administration as a coated tablet (SHB209 AB). Contraception 14:151–163PubMedCrossRefGoogle Scholar
  321. Spink DC, Lincoln II DW, Dickermann HW, Gierthy JF (1990) 2,3,7,8-Tetrachlorodibenzo-p-dioxin causes an extensive alteration of 17 {3-estradiol metabolism in MCF-7 breast tumor cells. Proc Natl Acad Sci USA 87:6917–6921PubMedCrossRefGoogle Scholar
  322. Srivastava AK, Agnihotri A, Kamboj VP(1984)Binding of centchroman - a nonsteroidal antifertility agent to human plasma proteins. Experientia 40:465–466PubMedCrossRefGoogle Scholar
  323. Stadel BV, Sternthal PM, Schiess Elmann, Douglas MB, Dallas Hall W, Kaul L, Ahluwalia B (1980) Variation of ethinylestradiol blood levels among healthy women using oral contraceptives. Fertil Steril 33:257–260PubMedGoogle Scholar
  324. Stanczyk FZ, Gale JA, Goebelsmann U, Nerenberg C, Matin S (1980) Radioimmunoassay of plasma ethinylestradiol in the presence of circulating norethindrone. Contraception 22:457–470PubMedCrossRefGoogle Scholar
  325. Studd JWW Smith RNJ (1993) Oestradiol and testosterone implants. Bailliere’S Clin Endocrinol Metab 7:203–223CrossRefGoogle Scholar
  326. Stumpf PG (1990) Pharmacokinetics of estrogen. Obstet Gynecol 75:9S–14SPubMedGoogle Scholar
  327. Suhonen SP, Allonen HO, Lahteenmaki P (1993) Sustained-release subdermal estradiol implants: A new alternative in estrogen replacement therapy. Am J Obstet Gynecol 169: 1248–1254PubMedGoogle Scholar
  328. Taioli E, Garte SJ, Trachman JETAL Etal. (1996) Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst 88:617PubMedCrossRefGoogle Scholar
  329. Takikawa H, Sano N, Tadokoro K, Yamanaka M (1996) Biliary excretion of estrone metabolites in the rat. Int Hepatol Commun 5:251–258CrossRefGoogle Scholar
  330. Tanaka Y, Sekiguchi M, Sawamoto T, Hata T, Esumi Y, Sugai S, Ninomiya S (1994) Pharmacokinetics of droloxifene in mice, rats, monkeys, premenopausal and postmenopausal patients. Eur J Drug Metab Pharmacokin 19:7–58CrossRefGoogle Scholar
  331. Tannenbaum SR (1997) Comparative metabolism of tamoxifen and DNA adduct formation and invitro studies on genotoxicity. Seminars in Oncology 24 (Suppl 1 ):Sl–81-S1-86Google Scholar
  332. Tamate K, Charleton M, Gosling JPETAL Etal. (1997) Direct colorimetric monoclonal antibody enzyme immunoassay for estradiol-17 {3 in saliva. Clin Chern 43:1159–1164Google Scholar
  333. Tenni P, Lalich DL, Byrne MJ(1989)Life threatening interaction between tamoxifen and warfarin. Br Med J 298:93CrossRefGoogle Scholar
  334. Tepper R, Goldberger S, Cohen IETAL Etal. (1994) Estrogen replacement in postmenopausal women: are we currently overdosing our patients?Gynecol Obstet Invest 38:113–116PubMedCrossRefGoogle Scholar
  335. Tess DA, Cole RO, Toler SM (1995) Sensitive method for the quantitation of droloxifene in plasma and serum by high-performance liquid chromatography employing fluorimetric detection. J Chromatogr B 674:253–260CrossRefGoogle Scholar
  336. Tetsuo M, Axelson M, Sjovall J (1980) Selective isolation procedures for GC/MS analysis of ethinylsteroids in biological material. J Steroid Biochem 13:847–860PubMedCrossRefGoogle Scholar
  337. Thomas CMG, van den Berg RJ, Segers MFGet a1. (1993) Inaccurate measurement of 17 ~ Estradiol in serum of female volunteers after oral administration of milligram amounts of micronized 17~Estradio1.Clin Chern 39:2341–2342Google Scholar
  338. Timmer CJ, Apter D, Voortman G (1990) Pharmacokinetics of 3-keto-desogestrel and ethinyletradiol released from different types of contraceptive vaginal rings. Contraception 42:629–642PubMedCrossRefGoogle Scholar
  339. Tolino A, Ronsini S, Granata P, Gallo FP, Riccio S, Montemagno U (1990) Topical treatment using estriol of post-menopausal atrophic vaginitis. (Franz).Rev Fr Gynecol Obstet 85:692–697PubMedGoogle Scholar
  340. Tominaga T, Abe 0, Izuo M, Nomura Y(1990)A phase I study of toremifene. Breast Cancer Res Treat 16 (Suppl):S27–S29CrossRefGoogle Scholar
  341. Tornatore KM, Kanarkowski R, McCarthy TL, Gardner MJ, Yurchak AM, Jusko WJ (1982) Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin PharmacoI23:129–134CrossRefGoogle Scholar
  342. Townsend RW, Keuth V, Embil Ket a1. (1988) High-performance liquid chromatographic determination of conjugated estrogens in tablets. J Chromatogr 450:414–419PubMedCrossRefGoogle Scholar
  343. Troy SM, Hicks DR, Parker VD, Jusko WJ, Rofsky HE, Porter RJ (1994) Differences in pharmacokinetics and comparative bioavailability between Premarin® and Estratab® in healthy postmenopausal women. Curr Ther Res 55:359–372CrossRefGoogle Scholar
  344. Tseng L, Gurpide E (1975) Induction of human endometrial estradiol dehydrogenase by progestins. Endocrinology 97:825–833PubMedCrossRefGoogle Scholar
  345. Turkes A, Dyas J, Read GF, Riad-Fahmy D (1981) Enzyme immunoassay for specific determination of the synthetic estrogen ethynyl estradiol in plasma. Clin Chern 27:901–905Google Scholar
  346. Vanluchene E, Vandekerckhove D, Jonckheere Jet a1. (1983) Steroid profiles of body fluids other than urine, obtained by capillary gas chromatography. J Chromatogr 279:573–580PubMedCrossRefGoogle Scholar
  347. Van Look PF, Top Huisman M, Gnodde HP(1981)Effect of ampicillin or amoxycillin administration on plasma and urinary estrogen levels during normal pregnancy. Eur J Obstet Gynecol Reprod Bioi 12:225–233CrossRefGoogle Scholar
  348. Warren RJ, Fotherby K (1973) Plasma levels of ethynylestradiol after administration of ethynylestradiol or mestranol to human subjects. J Endocrinol 59:369–370PubMedCrossRefGoogle Scholar
  349. Wasser SK, Monfort SL, Southers Jet a1. (1994) Excretion rates and metabolites of oestradiol and progesterone in baboon (Papio cynocephalus cynocephalus) faeces. J Reprod Fertil 101:213–220PubMedCrossRefGoogle Scholar
  350. Watanabe N, Irie T, Koyama M, Tominaga T (1989) Liquid chromatographicatmospheric pressure ionization mass spectrometric analysis of toremifene metabolites in human urine. J Chromatogr 497:169–180PubMedCrossRefGoogle Scholar
  351. Weber A, Jager R, Borner A, Klinger G, Vollanth R, Matthey K, Balogh A (1996) Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 53:41–47PubMedCrossRefGoogle Scholar
  352. Webster LK, Crinis NA, Stokes KH, Bishop JF (1991) High-performance liquid chromatographic method for the determination of toremifene and its major human metabolites. J Chromatogr Biomed Appl 565:482–487CrossRefGoogle Scholar
  353. White I, Muller-Eberhard H (1977) Decreased liver cytochrome PA50 in rats caused by norethindrone or ethynylestradio1. Biochem J 166:57–64PubMedGoogle Scholar
  354. White INH, Martin EA, Styles J, Lim C-K, Carthew P, Smith LL (1997) The metabolism and genotoxicity of tamoxifen. In:Aldaz CM, Gould MN, McLachlan J, Slaga TJ (eds)Etiology of breast and gynecological cancers. Wiley-Liss Inc., New York Chichester Weinheim Brisbane Singapore Toronto, pp 257–270Google Scholar
  355. Wiebe V, Benz CC, Shemano I, Cadman TB, DeGregorio MW (1990) Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chern other Pharmacol 25:247–251CrossRefGoogle Scholar
  356. Wiemeyer JC, Fernandez M, Moguilevsky JA, Sagasta CL (1986) Pharmacokinetic studies of estradiol enanthate in menopausic women. Arzneimittelforsch 36:1674–1677PubMedGoogle Scholar
  357. Williams JG, Williams KIH(1975)Metabolism of 2_3H- and 4_14C-17 a-ethynylestradiol 3-methyl ether (mestranol) by women. Steroids 26:707–720PubMedCrossRefGoogle Scholar
  358. Williams JG, Longcope C, Williams KIH (1975) Metabolism of 4-3H_ and 4_14C-17aethynylestradiol 3-methyl ether (mestranol) by women. Steroids 25:343–354PubMedCrossRefGoogle Scholar
  359. Williams MC, Helton ED, Goldzieher JW (1975) Chromatographic profiling and identification of ethynyl and non-ethynyl compounds. Steroids 25:229–246PubMedCrossRefGoogle Scholar
  360. Williams MC, Goldzieher JW (1980) Chromatographic patterns of urinary ethynyl estrogen metabolites in various popUlations. Steroids 36:255–282PubMedCrossRefGoogle Scholar
  361. Wiseman LR, Goa KL (1997) Toremifene A review of ist pharmacological properties and clinical efficiency in the management of advanced breast cancer. Drugs 54:141–160PubMedCrossRefGoogle Scholar
  362. Woolley DE, Holinka CF, Timiras PS (1969) Changes in 3H-estradiol distribution with development in the rat. Endocrinology 84:157–161PubMedCrossRefGoogle Scholar
  363. Yamamoto T, Honjo HETAL Etal. (1979) The metabolic fate of estradiol benzoate in female dog. J Steroid Biochem 11:1287–1294PubMedCrossRefGoogle Scholar
  364. Zamah NM, Humpel M, Kuhnz W, Louton T, Rafferty J, Back DJ (1993) Absence of an effect of high vitamin C dosage on the systemic availability of ethinyl estradiol in women using a combination oral contraceptive. Contraception 48:377–391PubMedCrossRefGoogle Scholar
  365. Zimmermann H, Koytchev R, Mayer 0, Borner A, Mellinger U, Breitbarth H (1998a) Pharmacokinetics of orally administered estradiol valerate. Results of a singledose cross-over bioequivalence study in postmenopausal women. Arzneimittelforsch 48(11):941–947Google Scholar
  366. Zimmermann H ETAL Etal. (1998b) Single and multiple dose pharmacokinetics of a sequential estradiol valerate / chlormadinone acetate preparation for hormone replacement therapy. (publication in preparation)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg New York 1993

Authors and Affiliations

  • W. Kuhnz
  • H. Blode
  • H. Zimmermann

There are no affiliations available

Personalised recommendations